- Home
- INKT vs GRF Comparison
INKT vs GRF Comparison
Compare INKT & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INKT | GRF |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 42.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | GRF |
|---|---|---|
| Price | $11.12 | $10.80 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 21.0K | 3.0K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $7.93 |
| 52 Week High | $76.00 | $10.19 |
Technical Indicators
Market Signals| Indicator | INKT | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 52.34 |
| Support Level | $10.84 | $10.70 |
| Resistance Level | $12.31 | $11.58 |
| Average True Range (ATR) | 0.61 | 0.35 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 18.14 | 25.41 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.